Recent developments spotlight CRISPR-Cas technologies evolving beyond genome editing into potent antibacterial agents. Leveraging the system's inherent viral defense mechanism, researchers are engineering CRISPR-Cas to precisely target and disable pathogenic bacteria, offering an innovative alternative to traditional antibiotics amid rising resistance. This expansion underscores CRISPR's transformative potential in infectious disease management and biotechnology.